complexity of GPCRs
Confo Therapeutics employs its proprietary CONFO® technology to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery. Confobody-stabilized active state conformations of these receptors reveal previously inaccessible structural features empowering the discovery of novel pathway-selective agonists for improved therapeutic intervention.
Confo Therapeutics is a drug discovery company building a unique pipeline of GPCR targeted therapeutics addressing unmet medical need.
Conformational challenges of GPCR drug discovery
Understanding the CONFO® technology
to appoint Chairman
dr. Christel Menet
Building E, 7th Floor, Room E7.6
1050 Brussels, Belgium
To join our talented team and become a part of our future success, please contact us